Walid Kamoun, Vice President, Global Head of R/D Oncology at Servier, shared a post on LinkedIn:
“I had the pleasure of participating in a recent R&D ON AIR session dedicated to Servier’s commitment to developing transformative therapies for patients with brain tumors.
During the discussion, I was delighted to be joined by Caroline Liot from our Oncology Research team, who shared insights into the scientific innovation driving our brain tumor research efforts, and by Anne Dagallier, Head of Business Development Oncology at Servier, who highlighted our ambition to be a partner of choice in brain tumors.
Brain cancers remain among the most challenging diseases in oncology, demanding bold science and strong partnerships. At Servier, our strategy is to combine internal research excellence, academic collaborations, external innovation, and strategic partnerships with biotech and pharmaceutical companies to accelerate the development of new treatment options for patients.
Thank you to everyone who joined this engaging discussion and to all those contributing every day to advancing innovation for patients.”
Other posts featuring Walid Kamoun on OncoDaily.
